Key result
Percutaneous patent foramen ovale closure demonstrates durable long-term safety and efficacy for associated cryptogenic stroke, though long-term bleeding risks require individualized antithrombotic strategies.
Why the study?
The persistently patent oval foramen has emerged as a clinically significant entity due to its association with cryptogenic stroke, and understanding has evolved over the past two decades from epidemiologic observations to risk stratification algorithms and an evidence base for therapeutic interventions.
Answers are grounded in this paper and cite their sources.
This narrative review synthesizes the pathophysiology, risk stratification (RoPE and PASCAL), and contemporary percutaneous closure strategies for patent foramen ovale-associated stroke, highlighting the need for individualized antithrombotic therapy to mitigate long-term bleeding risks.
The oval foramen, an integral component of the fetal cardiac circulation, remains persistently patent in approximately one-quarter of the adult population, thus producing an interatrial communication that potentially permits right-to-left shunting. Usually asymptomatic, the persistently patent foramen has emerged as a clinically significant entity due to its established association with cryptogenic stroke through paradoxical embolism. Over the past two decades, the evolution of our understanding regarding stroke associated with persistent patency has moved from epidemiologic observations to the creation of algorithms for stratification of risk, and has subsequently provided an evidence base for therapeutic interventions. In this review, we examine the embryological development and pathophysiology of persistent patency, clarifying a century-old contradiction. We then consider the clinical assessment and contemporary management of associated stroke, with particular emphasis on the score now provided for risk of paradoxical embolism, giving us the acronym RoPE, along with the classification system PASCAL. The latter acronym represents PFO (Patent Foramen Ovale)-Associated Stroke Causal Likelihood, and provides a guide for the selection of patients. We analyze the evidence underscoring percutaneous closure of the foramen, discussing the profiles of adverse events and emerging technologies. We include an evaluation of suture-mediated closure, which is currently used in smaller and highly selected populations, along with a discussion of more promising bioresorbable technologies. We also incorporate new data from the longest follow-up study to date, which confirms the durable safety and efficacy of device closure, while highlighting the critical issue of the long-term risk of bleeding, underscoring the need for individualized post-procedural antithrombotic strategies.
No takes yet. Share an insight, caveat, or question.
Calcaterra et al. (2026) conducted a review in Patent foramen ovale (PFO) and cryptogenic stroke. Percutaneous patent foramen ovale closure was evaluated. Percutaneous patent foramen ovale closure demonstrates durable long-term safety and efficacy for associated cryptogenic stroke, though long-term bleeding risks require individualized antithrombotic strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: